No Data
No Data
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (BLCO), Spyre Therapeutics (SYRE) and Herbalife (HLF)
Spyre Therapeutics Analyst Ratings
Leerink Partners Initiates Spyre Therapeutics With Outperform Rating, $45 Price Target
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, Its Novel Half-life Extended IL-23 Antibody
Wolfe Research Initiates Spyre Therapeutics at Outperform With $27 Price Target
Wolfe Research Initiates Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $27